Imperial Innovations Group Share News (IVO)

Imperial Innovation Looks To Raise GBP150.0 Million In Share Placing

LONDON (Alliance News) - Imperial Innovations Group PLC Monday detailed plans to raise up to GBP150.0 million before expenses through a share placing with new and existing investors, as it looks to support its existing portfolio companies, source opportunities to invest in new technologies, and f

Imperial Innovations 44% Owned Veryan Reports Positive Data

LONDON (Alliance News) - Imperial Innovations Group PLC Friday said the third-largest company in its portfolio is set to publish positive new data after a controlled study. In a statement, Imperial Innovations said that Veryan Medical will Friday publish the full two-year data from the Mimi

Imperial Innovations Says JustYoyo Has Completed Investment Round

LONDON (Alliance News) - Imperial Innovations Group PLC Thursday said its portfolio company JustYoyo has completed a GBP2.8 million seed investment round. The investment round for the mobile payments and loyalty company was completing with a second tranche investment, with the first investm

Imperial Innovations' Nexeon completes manufacturing facility

Imperial Innovations, the AIM-listed technology group, said that its portfolio company Nexeon has completed the construction and commissioning of its manufacturing facility at its headquarters in Oxfordshire.  Nexeon is Imperial's second-largest portfolio company and develops silicon anode techno

Imperial Innovations Says Nexeon Completes Construction Of Headquarters

LONDON (Alliance News) - Imperial Innovations PLC said Thursday its portfolio company Nexeon Ltd has completed the construction and commissioning of its process development and manufacturing facility at its headquarters in Oxfordshire. Nexeon is Innovations' second largest portfolio company

DIRECTOR DEALINGS: Imperial Innovations Non-Executive Buys Shares

LONDON (Alliance News) - Imperial Innovations Group PLC Thursday said Non-Executive director David Begg bought 1,470 shares at a price of 403 pence per share. Following this transaction, Begg now holds 21,319 shares, which represents 0.02% stake in the firm. Shares in the software com

Imperial Innovations Profit Jumps As Circassia Investment Pays Off

LONDON (Alliance News) - Imperial Innovations Group PLC Friday saw pretax profit rise in the half-year ended January 31, 2014, boosted by the success of its largest investment, Circassia Pharmaceuticals PLC. The technology investment company posted a pretax profit of GBP24.4 million, up fro

CORRECTED-UPDATE 2-Allergy drug firm Circassia prices London listing at top of range

(Corrects Reuters Instrument Code to in first paragraph) By Freya Berry LONDON, March 13 (Reuters) - British allergy drug development firm Circassia priced its initial public share offer at the top of its range on Thursday, in the biggest London market debut in years for a biotech com

Imperial Innovations' Circassia Prices IPO

LONDON (Alliance News) - Imperial Innovations Group PLC Thursday said its largest portfolio company, Circassia Pharmaceuticals, has successfully priced its IPO on the London Stock Exchange's Main Market. Circassia is expected to raise gross proceeds of about GBP200 million pounds in the pla

Imperial Innovations' Circassia to list on LSE main market

Clinical-stage specialty biopharmaceutical company Circassia has announced its intention to float on the London Stock Exchange's Main Market. The company is focused on the development and commercialisation of a range of immunotherapy products for the treatment of allergies, such as those to cats, g

UK MORNING BRIEFING: Vodafone Gains, AstraZeneca Falls At Open

LONDON (Alliance News) - Vodafone has delivered results in line with expectations Thursday morning, helping to give UK share a positive start. Vodafone is up 1.4%.

Meanwhile, AstraZeneca has opened down 2.1% after reporting lower revenue and profit

UPDATE 1-Circassia seeks $285 mln in bumper UK biotech IPO

* Allergy firm tests European market for larger biotech IPOs * Follows boom in biotech offerings in United States * Funds to help bring cat allergy vaccine to market By Paul Sandle LONDON, Feb 6 (Reuters) - Circassia, a company developing allergy treatments based on a disc

UK MORNING BRIEFING:

LONDON (Alliance News) - Vodafone has delivered results in line with expectations Thursday morning, helping to give UK share a positive start. Vodafone is up 1.4%.

Meanwhile, AstraZeneca has opened down 2.1% after reporting lower revenue and profit

Allergy drug firm Circassia seeks $285 mln in London IPO

LONDON, Feb 6 (Reuters) - Circassia, a company developing allergy treatments based on a discovery by scientists at Imperial College in London, plans to raise about 175 million pounds ($285 million) of new funds in a stock market debut to bring its cat allergy vaccine to market. Chief execut

AIM IN BRIEF: H&T Says Profit As Expected, But Gold Price Has Hurt